Regeneron Pharmaceuticals (REGN) DIvidends Date & History

Key Takeaways

• Modest, newly initiated dividend: Regeneron only began paying a quarterly dividend in early 2025, making it a young dividend stock rather than an established income play.
• Low yield around 0.5%: With a dividend of roughly $3.76 per share annually, REGN yields far below the broader market and its large-cap pharmaceutical peers.
• Very conservative payout ratio: The company distributes only about 8–9% of earnings, leaving ample room for future increases.
• Early growth signal: Regeneron raised its quarterly payout from $0.88 to $0.94 per share in 2026, an increase of roughly 6.8%.
• Share buybacks dominate returns: Regeneron returns far more cash through repurchases than dividends, so total shareholder yield is more meaningful than the dividend yield alone.

Dividend Overview

Regeneron Pharmaceuticals (REGN) is a leading biotechnology company best known for blockbuster medicines such as EYLEA and Dupixent. For most of its history, the company returned capital exclusively through share buybacks, but it initiated its first-ever quarterly dividend in early 2025, with an initial payout of $0.88 per share. In 2026 it increased the quarterly dividend to $0.94 per share, bringing the annualized payout to roughly $3.76 and producing a dividend yield near 0.5%.

Dividends are paid quarterly, and the most recent declared payment had an ex-dividend date of August 18, 2026, with payment on August 31, 2026. Regeneron is best described as a company with a modest, still-maturing dividend rather than a high-yield stock or an established dividend growth stock. Its low payout ratio and strong cash generation, however, suggest the dividend has room to grow over time.

Dividend History and Growth

Because Regeneron only began distributing cash dividends in 2025, its dividend history is short. The company launched the payout at $0.88 per share per quarter, then lifted it to $0.94 per share in 2026 — a year-over-year increase of about 6.8%. That early raise is a positive signal, indicating management intends to build a consistent, growing dividend rather than treating the payment as a one-time gesture.

Still, investors should view Regeneron as an emerging dividend payer. It does not yet carry a multi-year dividend growth streak, and its five-year dividend growth rate is essentially zero simply because no dividend existed before 2025. The company's long-term strategy appears to combine a gradually rising dividend with substantial share repurchases, which together drive total shareholder returns.

Dividend Sustainability and Payout Ratio

Regeneron's dividend looks highly sustainable by conventional measures. The payout ratio — the share of earnings distributed as dividends — stands at roughly 8–9%, one of the lowest among dividend-paying large caps. With trailing earnings per share (EPS) around $14, the annual dividend of approximately $3.76 is covered many times over. The free cash flow payout ratio is similarly low, near 10%, meaning the company could comfortably fund its dividend from operating cash flow.

Regeneron also carries a strong balance sheet with significant cash and investments, providing additional cushion. Because the dividend consumes only a small fraction of earnings and free cash flow, Regeneron has considerable flexibility to raise the payout even during periods of uneven drug revenue. The primary limitation on future dividend growth is likely strategic — management may prefer to prioritize buybacks and research and development (R&D) investment — rather than any financial constraint.

Dividend Compared to Industry Peers

Within biotechnology, Regeneron's dividend is relatively rare and, at roughly 0.5%, sits above many biotech peers that pay no dividend at all. Compared with larger, more mature pharmaceutical and biotechnology companies, however, the yield is low. For example, AMGN (Amgen), GILD (Gilead Sciences), ABBV (AbbVie), and JNJ (Johnson & Johnson) all typically yield in the low-to-mid single digits — several times Regeneron's payout.

The gap reflects different business models. Regeneron, like many biotechs, channels the bulk of its profits into R&D and share repurchases rather than dividends. As a result, its dividend profile is closer to that of a growth-oriented biotech beginning to return cash than to an income-oriented pharmaceutical giant. Investors comparing yields across the sector should weigh this distinction carefully.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can also help identify dividend stocks, income-focused investments, trending stocks, and breakout candidates more efficiently than manual screening. Explore the AI Screener to refine your search for income and growth opportunities that match your criteria.

Is This Stock Attractive for Dividend Investors?

Regeneron is unlikely to appeal to income investors who need meaningful current yield, since a payout near 0.5% provides minimal cash flow relative to the share price. The stock is better suited to total-return investors and long-term dividend growth investors who are willing to accept a small yield today in exchange for the potential of compounding payout increases over time.

The company's extremely low payout ratio, strong cash generation, and early dividend increase suggest management has ample capacity to grow the dividend for years to come. However, because the dividend is new and the yield is small, Regeneron does not yet offer the characteristics conservative income investors often seek — such as a long track record of uninterrupted payments or a defensive, above-average yield. Investors evaluating Regeneron should view the dividend as a complementary feature of a growth-oriented biotechnology holding rather than as the central reason to own the stock.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations